Method for the treatment of dravet syndrome

Patent metadata

Field	Value
Publication number	US-9549909-B2
Application number	US-201313887014-A
Country	US
Kind code	B2
Filing date	May 3, 2013
Priority date	May 3, 2013
Publication date	Jan 24, 2017
Grant date	Jan 24, 2017

Abstract

A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.

First claim

The invention claimed is:

1. A method of ameliorating seizures in a patient diagnosed with Dravet syndrome, comprising:
orally administering an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof;
orally administering an effective dose of stiripentol or a pharmaceutically acceptable salt thereof to said patient;
orally administering an effective dose of valproate or a pharmaceutically acceptable salt thereof to said patient; and
orally administering an effective dose of clobazam or a pharmaceutically acceptable salt thereof to said patient,
whereby seizures are ameliorated in the patient.

2. The method of claim 1 , wherein the fenfluramine or pharmaceutically acceptable salt thereof is administered in a dose of 0.5 mg/kg/day to 0.01 mg/kg/day to the patient.

3. A method of ameliorating seizures in a patient diagnosed with Dravet syndrome, comprising:
orally administering a liquid formulation comprised of an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof;
orally administering an effective dose of stiripentol or a pharmaceutically acceptable salt thereof to said patient;
orally administering an effective dose of valproate or a pharmaceutically acceptable salt thereof to said patient; and
orally administering an effective dose of clobazam or a pharmaceutically acceptable salt thereof to said patient,
wherein the fenfluramine or pharmaceutically acceptable salt thereof is administered in a dose of 0.5 mg/kg/day to 0.01 mg/kg/day to the patient,
whereby seizures are ameliorated in the patient.

Assignees

• Univ Leuven Kath
• Univ Hospital Antwerp
• The Katholieke Univ Leuven

Inventors

• Ceulemens Berten
• Lagae Lieven

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61K31/36

  Compounds containing methylenedioxyphenyl groups, e.g. sesamin · CPC title

• A61K31/137 Primary

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K31/5513 Primary

  1,4-Benzodiazepines, e.g. diazepam {or clozapine} · CPC title